Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Uses Allergan Stage In Campaign To Keep Focus On Industry's Reputation For Innovation

Executive Summary

PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.

You may also be interested in...



Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity

The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.

Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument

Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel